Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials
NCT ID: NCT05602090
Last Updated: 2023-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2022-02-01
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
NCT00493961
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
NCT00517062
Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion
NCT02655263
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
NCT04648969
Growth Hormone and Glucose Metabolism
NCT00929799
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Growth Hormone adjuvant treatment
Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
4 IU of recombinant GH (Somatotropin )
4 IU of recombinant GH
control
standard controlled ovarian stimulation
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
4 IU of recombinant GH (Somatotropin )
4 IU of recombinant GH
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Advanced maternal age (40years).
2. A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation
3. An abnormal ovarian reserve test (ORT)
* antral follicle count (AFC)\<7 or
* anti-Müllerian hormone (AMH)\<1.1ng/ml.
Exclusion Criteria
2. Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment)
4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity. 6- Basal FSH more than 17 IU. 7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Abdallah Mohamed Salem
Lecturer of Gynecology and obstetrics Faculty of medicine Beni-Suef University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beni-Suef University
Role: STUDY_CHAIR
Faculty of Medicine Beni-Suef University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni-suef university
Banī Suwayf, Beni Suweif Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMBSUREC/01022022/Hemida
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.